 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C5H9N3 |
| Molecular Weight | 111.15 |
| Exact Mass | 111.08 |
| CAS # | 105-20-4 |
| Related CAS # | Betazole dihydrochloride;138-92-1 |
| PubChem CID | 7741 |
| Appearance | Colorless to light yellow ointment |
| Density | 1.14g/cm3 |
| Boiling Point | 284.1ºC at 760mmHg |
| Melting Point | 25°C |
| Flash Point | 150.3ºC |
| Vapour Pressure | 0.00303mmHg at 25°C |
| Index of Refraction | 1.567 |
| LogP | 0.611 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 2 |
| Heavy Atom Count | 8 |
| Complexity | 64.7 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C(CN)C1=NNC=C1 |
| InChi Key | JXDFEQONERDKSS-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C5H9N3/c6-3-1-5-2-4-7-8-5/h2,4H,1,3,6H2,(H,7,8) |
| Chemical Name | 2-(1H-pyrazol-5-yl)ethanamine |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | H2 Receptor |
| ln Vitro | With only a little amount of H1 activity and a significant selectivity towards H2 receptors, betzole (Ametazole) is a weak histamine agonist. The gastric inhibitory polypeptide (GIP) is secreted in response to betzole[1]. |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion Rapid and complete. |
| Toxicity/Toxicokinetics |
Protein Binding > 99% |
| References |
[1]. Maples MD, Effects of betazole hydrochloride and cimetidine on common bile pressure and duodenal myoelectric activity in the dog. Am Surg. 1981;47(12):519-521. [2]. Spitz IM, Betazole-induced GIP secretion is not mediated by gastric HCl. Metabolism. 1982;31(4):380-382. [3]. CLAYMAN CB,. A simple oral gastric secretory stimulant (betazole hydrochloride). JAMA. 1961;175:908-909. |
| Additional Infomation |
Betazole is pyrazole in which a hydrogen adjacent to one of the nitrogen atoms is substituted by a 2-aminoethyl group. It is a histamine H2-receptor agonist used clinically to test gastric secretory function. It has a role as a histamine agonist, a diagnostic agent and a gastrointestinal drug. It is a member of pyrazoles and a primary amino compound. A histamine H2 agonist used clinically to test gastric secretory function. Betazole is a histamine H2 receptor agonist with diagnostic application. Betazole selectively targets and binds to the H2 receptor, thereby mimicking the effect of histamine on these receptors. This may lead to an increase in gastric secretions. Betazole can be used in gastric function tests. A histamine H2 agonist used clinically to test gastric secretory function. Drug Indication For use clinically to test gastric secretory function. Mechanism of Action Betazole is a histamine analogue. It produces the same effects as histamine, binding the H2 receptor which is a mediator of gastric acid secretion. This agonist action thereby results in an increase in the volume of gastric acid produced. Pharmacodynamics Betazole is a histamine H2 agonist used in a test for measuring maximal production of gastric acidity or anacidity. This measurement can be used to diagnose diseases such as Zollinger-Ellison syndrome, whereby the volume of gastric and basal secretions is measured following betazole administration (greater than 60% of the maximal acid secretion following betazole stimulation). In another test, gastritis can be diagnosed given late absence of gastric acid which is unresponsive to betazole stimulation. Betazole can be used as a gastric secretory stimulant instead of histamine with the advantage of not provoking side effects and thus not requiring the use of antihistaminic compounds. |
Solubility Data
| Solubility (In Vitro) | DMSO: 250 mg/mL (2249.21 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (18.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (18.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (18.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.9969 mL | 44.9843 mL | 89.9685 mL | |
| 5 mM | 1.7994 mL | 8.9969 mL | 17.9937 mL | |
| 10 mM | 0.8997 mL | 4.4984 mL | 8.9969 mL |